LOS ANGELES, May 20 (Reuters) - Treatment with Ziopharm Oncology Inc's (ZIOP.O) experimental drug delayed by 77 percent the time it took for sarcoma tumors to grow, according to results from a mid-stage study.
Patients treated with a combination of the Ziopharm drug, palifosfamide, and chemotherapy drug doxorubicin, lived for a median of 7.8 months before their cancer worsened, compared with 4.4 months for the group treated only with doxorubicin....
By Crystal Phend, Senior Staff Writer, MedPage Today
Published: April 28, 2010
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston.
Heating the area around a high-risk soft-tissue sarcoma during chemotherapy can boost antitumor efficacy and improve survival, researchers found.
Regional hyperthermia during induction was associated with a 42% reduction in risk of local progression or death compared with chemotherapy...
Milan (Italy), 13 April 2010 – MolMed S.p.A. (Milan:MLM) announces the treatment of the first patient in a pivotal Phase III trial (NGR015) of its investigational antitumour drug NGR-hTNF in malignant pleural mesothelioma, a condition linked with repeated exposition to asbestos fibers.
Claudio Bordignon, MolMed’s chairman and CEO, comments: “We are really proud of this important milestone, as NGR-hTNF may represent a novel treatment option for malignant mesothelioma,...
Renal & Urology News
Caroline Helwick
February 05, 2010
NEW ORLEANS—Acute renal failure (ARF) induced by pathogenic light chains can be the first presenting sign of multiple myeloma, and prompt treatment of the malignancy is critical to reversing renal damage, according to a study presented by European investigators at the American Society of Hematology 51st annual meeting.
“This is an oncologic emergency and you need very active myeloma treatment to correct...
Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
Businesss Wire
February 03, 2010 09:00 AM Eastern Time
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy...
